Survival rates are lower for patients with high-risk melanoma with mutations
the ONA take:
Researchers from UNC Lineberger Comprehensive Cancer Center analyzed melanoma samples to determine if tumors with the BRAF or NRAS gene mutations indicated poorer prognosis for those patients.
This study was conducted before new treatments for melanoma were approved, including the first BRAF inhibitor approved in 2011. Therefore, the connection between the mutations and outcomes were determined without the influence of the new drugs.
In this study, 912 patients with melanoma were followed for 7 years. All the patients were enrolled through the GEM study, and their diagnoses were made in 2000.
Thirteen percent of patients had tumors with NRAS mutations, 30% had BRAF mutations, and 57% had neither mutation. The researchers found that 73% of patients with high-risk, NRAS-mutated tumors and 71% of patients with high-risk, BRAF-mutated tumors survived 5 years, compared with 82% of high-risk tumors with neither mutation.
Overall, no statistical difference was seen in 5-year survival for people with NRAS or BRAF mutations compared with those people who had no mutation.
However, 5-year survival was lower in people with high-risk tumors with mutations.
No statistical difference was seen in 5-year survival for melanoma patients with NRAS or BRAF mutations.
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Online Learning Modules Improve Exercise Counseling, But Not Participation
- ASCO Issues Statement Addressing Alcohol and Cancer
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- Drug Combination Does Not Extend Glioblastoma Survival
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|